Oxartis Ltd

Oxartis is in pre-clinical stages of developing a new therapeutic modality of regenerative biomaterial, which exploits selective cell adhesion and morphological response, to orchestrate regenerative tissue reconstruction. Our core technology lies in fabrication of nano-fibre based tissue scaffolds with hierarchical porosity, from functional native-state proteins.
Additionally,
- We welcome requests for experimental or bespoke scaffolds, which can be presented in formats ranging from glass coverslips, multiwell plates to larger sponges.
- We offer service access to our Scanning Electron Microscope for rapid imaging needs or longer term projects.

Also, we host research student projects and Internships, and run Innovation open day visits for university student groups.

We are addressing the problem of skin-loss wounds, suffered by millions of patients world-wide. In the Uk, the NHS treats 4.6 million wounds per year. Having a serious wound matters individually because it interrupts normal life. Wounds cause pain, incapacity, loss of independence and loss of self-confidence, even though these issues arise differently depending on the context of the wound, e.g. burns, trauma, surgery or chronic ulceration. Wound matter economically because they consume a large portion of healthcare resource. The HNS currently spends around £12 bn/y on woundcare, which is 2/3 the total budget for cancer care. However, the incidence of wounds is rising year-on-year, outstripping healthcare resources, making delivery of even current standards of diagnostically appropriate treatment increasingly challenging.

The market is ready for an effective regenerative treatment which will improve outcomes through robust tissue reconstruction and accelerated heaing. Oxartis is in pre-clinical stages of developing ProMatrix BioDerm, a new therapeutic modality, which exploits selective cell adhesion and morphological response, to orchestrate regenerative tissue reconstruction Evidence in a pre-clincal large animal wound model shows categorical superiority in outcomes of excision wounds treated with grafts of ProMatrix compared to two leading clinical scaffolds or dressing alone.

We foresee huge potential for ProMatrix, should pre-clinical results translate to to the clinic, in increasing the rate of healing for chronic ulcers, and preventing scarring, for acute wounds from surgery, trauma or burns. A biomaterial to help people get back to normal lives faster and with less trauma.